December 5, 2019 4 Factors Associated With Ankylosing Spondylitis Progression Nearly one-quarter of patients with ankylosing spondylitis experienced disease progression over time, with male sex, presence of baseline damage, active disease state, and higher inflammatory markers predictive of spinal progression, while treatment with tumor necrosis factor (TNF) inhibitors slowed the progression rate, say researchers recently writing in Arthritis Care & Research. Learn more   ADVERTISEMENT Sustained Remission in RA Fails with Programmed Infliximab Treatment A new discontinuation strategy for infliximab in patients with rheumatoid arthritis, in which the biologic dose was determined by the serum level of tumor necrosis factor (TNF)-α, was unsuccessful for sustained biologic-free remission, say researchers recently writing in Annals of the Rheumatic Diseases. Learn more   MORE FROM RHEUMATOLOGY NETWORK • Ultra-Low Rituximab Dose in RA Fails to Meet Non-Inferiority • JIA Disease Activity Persists, Despite Lower Uveitis, Major Joint Surgery Rates • Exercise Protects Cognition in Patients with Rheumatoid Arthritis • RA Patients Still Have a "Considerable Need" for Treat-to-Target Care   RHEUMATOLOGY HEALTHCARE JOB OPPORTUNITIES Visit Rheumatology Network for easy access to new job opportunities in rheumatology. As a service to our readers, we've posted a national "Job Board" in the upper right-hand corner of the site. Suggestions for other content sections? Email the editor at areyes@mmhgroup.com.